Pantarhei Oncology proudly announces that its paper ‘Tumor Suppression, Dose Limiting Toxicity and Wellbeing with the Fetal Estrogen Estetrol (E4) in patients with advanced breast cancer’ has been accepted for publication in the Journal of Cancer Research and Clinical Oncology after comprehensive review. The Journal of Cancer Research and Clinical Oncology is an international peer-reviewed scientific journal in the field of oncology.
The research paper states that treating postmenopausal women diagnosed with advanced breast cancer can be treated safely with high doses of E4. All 12 patients enrolled had progressive, heavily pre-treated advanced breast cancer. No treatment-related serious adverse events or doses of limiting toxicity (DLTs) occurred during the first 4 weeks of E4 treatment allowing further investigation of all three doses. Five of nine patients completing 12 weeks of E4 treatment showed objective anti-tumor effects and six of nine patients reported improved wellbeing.
The Journal of Clinical Endocrinology & Metabolism has accepted the manuscript “Breast Cancer and Major Deviations of Genetic and Gender-related Structures and Function” by Herjan J.T. Coelingh Bennink, Jan F.M. Egberts, Jan A. Mol, Kit C.B. Roes, Paul J. van Diest for publication. The review reports of the risk of breast cancer (BC) in relation to gender, breast development and gonadal function in eight populations with different genetic conditions. Main three conclusions are: 1) the presence of an Y chromosome protects against the development of BC; 2) Without menstrual cycles, BC hardly occurs with an incidence comparable to males; 3) BC has been reported only once in genetic females with the Mayer-Rokitansky-Küster-Hauser syndrome, who have normal breasts and ovulating ovaries with normal levels of estrogens and progesterone.
For more information, please read the abstract.
On May 14, 2020, the last patient has had his last study visit for the phase IIa clinical study of Pantarhei assessing the efficacy and safety of the fetal estrogen estetrol (E4) in prostate cancer patients. The study, the PCombi study, is a double-blind, randomised, placebo-controlled, multi-centre study in patients treated with hormone therapy, an luteinising hormone-releasing hormone (LHRH) agonist, for their prostate cancer.
The main objectives of this study are to evaluate the additional effect of E4 on testosterone suppression by the LHRH agonist as well as the prevention and treatment of hypoestrogenic side effects (e.g. hot flushes) due to the concomitant suppression of estrogens.
First results are expected to be available by beginning of August this year.